Guide

Nausea on a GLP-1: What the Trials Recorded and When It Matters

Nausea was reported by 29% of participants at tirzepatide 15 mg in SURMOUNT-1, mostly mild to moderate and concentrated around dose increases rather than spread evenly. I

What the trials recorded

In SURMOUNT-1 at the 15 mg dose: nausea in 29% of participants, diarrhoea 23%, constipation 17%, vomiting 13%, dyspepsia 10%. Most events were mild to moderate.

The distribution matters more than the headline percentage. Gastrointestinal events clustered during dose escalation rather than persisting evenly through the trial, which is why the first twelve to twenty weeks are the hard part for most people and why discontinuation happens there.

Across doses, 4.3% to 7.1% of participants discontinued because of an adverse event, against 2.6% on placebo. At the top dose that is roughly one in fourteen.

Why it happens

These drugs slow gastric emptying and act on receptors involved in appetite and satiety signalling. That is the mechanism producing the intended effect, and nausea is the same mechanism experienced as a symptom.

It is dose-related, which is the single most useful thing to know. More drug generally means more of both the effect and the symptom, and that relationship is why the titration schedule exists at all.

The label detail that gets skipped

The tirzepatide label directs increases in 2.5 mg increments no sooner than every four weeks, based on tolerability and response. That is a minimum interval, not a schedule.

Nothing requires reaching 15 mg. The recommended maintenance dosages are 5, 10 and 15 mg — three destinations, not one. A programme escalating on a fixed calendar without assessing how you are doing is not following the label's logic, and that is worth raising directly.

The pancreatitis signal, quantified

Severe abdominal pain radiating to the back appears in the safety sections of these labels because of pancreatitis, and until recently the public numbers were vague. They are now less so.

On 29 January 2026 the UK medicines regulator updated GLP-1 product information and issued a drug safety alert highlighting that acute pancreatitis is a known but infrequent side effect that can be fatal, and urging patients and clinicians to be alert to severe, persistent stomach pain that may radiate to the back and may be accompanied by nausea and vomiting.

Between January 2023 and June 2026 there were 1,176 reported cases of acute and chronic pancreatitis following tirzepatide use, 18 of which had a fatal outcome.

Two things about reading that figure honestly. Spontaneous reporting systems capture a fraction of events and do not establish causation, so this is a signal rather than an incidence rate. And it sits against many millions of patient-months of exposure, so "infrequent" is accurate.

What it does establish is why the symptom description in the label is specific rather than generic. Severe, persistent abdominal pain radiating to the back is not a symptom to wait out, and that is the practical consequence of this data.

Expected, contact, urgent

Expected and usually improving: nausea in the days after a dose increase, reduced appetite, early fullness, mild fatigue during escalation.

Contact your prescriber: nausea that does not settle between doses, vomiting that limits fluids, dizziness on standing, weight falling faster than expected, or anything that makes you consider stopping.

Urgent, same day: severe abdominal pain particularly radiating to the back, which the label flags in connection with pancreatitis; persistent vomiting with signs of dehydration; severe right-upper abdominal pain with fever or jaundice, which the label flags for gallbladder disease.

What to bring to your prescriber

1. Which dose you are on and how long you have held it.
2. Which day you inject and when symptoms start relative to it.
3. Whether it settles before the next dose or persists through.
4. Whether you are able to keep fluids down.
5. Whether it is limiting what you eat to the point of inadequate intake.

That pattern tells a prescriber whether to hold, slow the increase, or reconsider. "It makes me feel sick" does not.

The options that exist between continuing and stopping

Holding at the current dose rather than advancing. Returning to a previously tolerated dose. Extending the interval beyond four weeks, which the label permits since four weeks is a minimum. Or, with a prescriber's involvement, considering whether a different agent suits you better — tolerability does not transfer between these drugs and someone who struggles with one may do well on another.

People stop because they believe the choice is continue-as-you-are or quit. It usually is not.

Questions readers actually ask